Health Discovery Corporation (OTCBB: HDVY) today announced the appointment of John R. Hadden to the position of Senior Vice President of National and International Business Development. An industry veteran with more than 26 years experience, Hadden brings to Health Discovery Corporation (HDC) a record of innovation and successes in the laboratory and healthcare fields. In his new role, Hadden is tasked with sales leadership and licensing of the Company’s products and technologies to clinical labs and medical diagnostics testing companies world-wide. He is also responsible for developing strategic alliances with these and other partners.

Most recently with Quest Diagnostics (NYSE: DGX), one of the largest commercial clinical laboratories in the world, Mr. Hadden oversaw a variety of wide-ranging assignments that included new product introductions, sales leadership, strategic alliances, and mergers and acquisitions. A former “Best of Quest” award winner, Mr. Hadden excelled at Quest for nearly eight years.

Prior to Quest Diagnostics, Mr. Hadden was Senior Vice President of Business Development at American Medical Laboratories, Inc. which was acquired by Quest Diagnostics in a transaction valued at $500 million. In addition, Mr. Hadden was Senior Vice President of National Business Development with LabOne, Inc. which was acquired by Quest Diagnostics in a transaction valued at $934 million. He also served as Associate Vice President for Laboratory Corporation of America (LabCorp).

“Throughout an impressive career with global, national and regional commercial clinical laboratories, John has accomplished a striking track record of success in all areas, from new product launches and sales leadership to mergers and acquisitions,” notes Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “We are thrilled to have his expertise to catapult the commercialization of Health Discovery’s products and technologies and to create strategic alliances driving the future of the Company.”

“I am honored to join Health Discovery Corporation and its distinguished team of world-renowned leaders and innovators at this very exciting time in the Company's development and commercialization cycle,” stated John Hadden, Senior Vice President for National and International Business Development. “I look forward to working closely with Dr. Barnhill to help bring commercial success to the tremendous pipeline of products, as well as developing strategic relationships to advance the goals of the Company.”

Mr. Hadden’s compensation, among other things, will include both monthly compensation as well as an equity component. The equity component is composed of one million warrants issuable upon the closing of a merger with or purchase of a CLIA Certified laboratory approved by The Board of Directors. An additional equity award of one million warrants will be issuable when the company’s stock price reaches $0.75 per share.

A native of Tampa, Florida, Mr. Hadden is an avid public and motivational speaker that has addressed crowds as a national spokesperson for March of Dimes, where he serves as Communications Chair; graduation speaker at Saint Petersburg College; and a repeat keynote speaker for Future Business Leaders of America, to name a few. Hadden holds a Bachelor’s of Science in Business Administration.

Health Discovery Corporation holds 50 issued patents and 40 pending patents related to its SVM and SVM-RFE development tools. For more information about its products, joint ventures and latest news, visit

About Health Discovery Corporation

Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company's Securities and Exchange Commission filings.

All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.

Copyright Business Wire 2010